ストックスクリーナーアプリを入手
23.50
1.59%
-0.38
アフターアワーズ：
22.15
-1.35
-5.74%
Ultragenyx Pharmaceutical Inc (RARE) 最新ニュース
Earnings call transcript: Ultragenyx Q4 2025 sees revenue growth, stock dips - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming DeadlinesRARE - PR Newswire
Ultragenyx (RARE) Reports Q4 Earnings: What Key Metrics Have to Say - Nasdaq
Earnings Flash (RARE) Ultragenyx Pharmaceutical Posts Q4 EPS -$1.29, vs. FactSet Est of -$1.09 - marketscreener.com
Ultragenyx (RARE) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance Australia
Ultragenyx (RARE) Revenue Forecasts Highlight Crysvita and Dojolvi Growth - GuruFocus
Ultragenyx Pharmaceutical Q4 Net Loss Narrows, Revenue Rises; Plans Job Cuts - marketscreener.com
Ultragenyx shares fall as 2026 revenue guidance misses expectations - Investing.com
Ultragenyx shares fall as 2026 revenue guidance misses expectations By Investing.com - Investing.com India
Ultragenyx Pharmaceutical Inc. Sued for Securities Law - GlobeNewswire
Ultragenyx (RARE) Q4 Revenue Surpasses Expectations, Prepares fo - GuruFocus
Ultragenyx Pharma Loss Narrows; To Cut 10% Of Workforce - Nasdaq
Ultragenyx: Q4 Earnings Snapshot - WWLTV.com
Ultragenyx Launches Restructuring Plan to Cut Costs - TipRanks
Ultragenyx Pharmaceutical Q4 Earnings Report: What Investors Need to Know - Benzinga
Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update - GlobeNewswire
Investors in Ultragenyx Pharmaceutical Inc. Should Contact The Gross Law Firm Before April 6, 2026 to Discuss Your RightsRARE - PR Newswire
RARE Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against Ultragenyx Pharmaceutical Inc. (RARE) - The Malaysian Reserve
Portnoy Law Firm Announces Class Action on Behalf of Ultragenyx Pharmaceutical, Inc. Investors - GlobeNewswire
Ultragenyx earnings in focus as gene therapy hopes offset drug flop - Investing.com Nigeria
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors - GlobeNewswire
Ultragenyx: Fourth Quarter Financial Overview - Bitget
Class Action Lawsuit Filed Against Ultragenyx Pharmaceutical - Intellectia AI
Class Action Announcement for Ultragenyx Pharmaceutical - GlobeNewswire
Earnings Outlook For Ultragenyx Pharmaceutical - Benzinga
Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
Ultragenyx Pharmaceutical Inc. Securities Class Action Lawsuit Filed; Lead Plaintiff Deadline April 6, 2026 – RGRD Law - GlobeNewswire
RARE SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - The Malaysian Reserve
Levi & Korsinsky Notifies Shareholders of Ultragenyx Pharmaceutical Inc.(RARE) of a Class Action Lawsuit and an Upcoming Deadline - PR Newswire
Ultragenyx Pharmaceutical Inc. (RARE): Investor Outlook Reveals a Promising 168% Potential Upside - DirectorsTalk Interviews
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 - GlobeNewswire
RARE Investors: Kessler Topaz Meltzer & Check, LLP Reminds Investors of April 6, 2026 Deadline in Se - PharmiWeb.com
RARE Investors: Kessler Topaz Meltzer & Check, LLP Reminds Investors of April 6, 2026 Deadline in Securities Fraud Class Action Lawsuit Filed Against Ultragenyx Pharmaceutical Inc. - The AI Journal
Stock Traders Buy Large Volume of Ultragenyx Pharmaceutical Put Options (NASDAQ:RARE) - MarketBeat
STOCKHOLDER ALERT: Pending Securities Fraud Lawsuit Against Ultragenyx Pharmaceutical Inc. (RARE) - marketscreener.com
INVESTOR ALERT: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP AnnouncesRARE - PR Newswire
Candriam S.C.A. Boosts Stake in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Lawsuit - The Malaysian Reserve
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionRARE - TMX Newsfile
RARE Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the ... - Caledonian Record
RARE Class Action Notice: Robbins LLP Reminds Investors of - GlobeNewswire
Ultragenyx’s Gene Therapy Shows Long-Term Efficacy in Two Sanfilippo Studies - BioSpace
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm - The Malaysian Reserve
Ultragenyx Pharmaceutical Class Action Lawsuit Announced - Intellectia AI
Ultragenyx Pharmaceutical (RARE) resubmits biologics license application for gene therapy treatment - MSN
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. ... - Caledonian Record
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
William Blair Maintains a Buy on Ultragenyx Pharmaceutical (RARE) - MSN
RARE SHAREHOLDER ACTION: Faruqi & Faruqi, LLP Reminds Ultragenyx (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - TMX Newsfile
Quant snapshot: Manulife, KBC, Ambev lead strong buys as Ultragenyx, Atomera lag - Seeking Alpha
Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx - GlobeNewswire
2026-02-08 | RARE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Ultragenyx Pharmaceutical Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:RARE | Press Release - Stockhouse
INVESTOR NOTICE: Ultragenyx Pharmaceutical Inc. (RARE) - GlobeNewswire
Ultragenyx Pharmaceutical (RARE) Resubmits Biologics License Application for Gene Therapy Treatment - Finviz
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc.RARE - The Malaysian Reserve
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With - GuruFocus
Ultragenyx Puts BLA for MPS IIIA Gene Therapy UX111 in Front of FDA Again - CGTLive®
13 Best Revenue Growth Stocks to Buy Right Now - Insider Monkey
INVESTOR DEADLINE: Ultragenyx Pharmaceutical Inc. (RARE) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces - ChartMill
Berger Montague PC Investigating Claims on Behalf of Investors in Ultragenyx Pharmaceutical Inc. After Class Action Filing (NASDAQ: RARE) - marketscreener.com
RARE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Ultragenyx Pharmaceutical Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - accessnewswire.com
Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – RARE - MEXC
RARE Investor Alert: Faruqi & Faruqi, LLP Reminds Ultragenyx (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - PR Newswire
Class Action Lawsuit Reminder Against Ultragenyx Pharmaceutical Inc. - Intellectia AI
Ultragenyx Pharmaceutical Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your Rights – RARE - marketscreener.com
User - The Chronicle-Journal
2026-02-06 | RARE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Ultragenyx Pharmaceutical Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:RARE | Press Release - Stockhouse
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):